METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Clinical trials for METASTATIC BREAST CANCER ( HER2 NEGATIVE) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC BREAST CANCER ( HER2 NEGATIVE) trials appear
Sign up with your email to follow new studies for METASTATIC BREAST CANCER ( HER2 NEGATIVE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets Tough-to-Treat breast cancer
Disease control Recruiting nowThis study is testing whether a combination of two existing cancer drugs, tucatinib and trastuzumab, can help control advanced breast cancer that has a specific genetic change (an ERBB3/HER3 mutation) but is not the typical HER2-positive type. It is for people whose cancer has sp…
Matched conditions: METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Apr 03, 2026 19:55 UTC
-
Blood test could personalize cancer care, help doctors decide when to change treatment
Disease control Recruiting nowThis study is testing if a simple blood test can help doctors make better treatment decisions for people with advanced breast cancer that has spread. Researchers will track tiny pieces of cancer DNA in the blood to see if changes can predict how well a treatment is working early …
Matched conditions: METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New scan could tell doctors which cancer drugs will work
Knowledge-focused Recruiting nowThis study is testing whether two types of PET scans can predict if a new class of targeted drugs will work for patients with advanced breast cancer. Researchers will scan 45 patients before they start treatment to see if the scan results match how well the drugs control their ca…
Matched conditions: METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:31 UTC